bpc-157 immunogenicity risks fda Heal or Harm: Body Protective Compound-157 in the Gray Zone FDA Briefing Document Pharmacy Compounding

Eliminating feature selection reduced MCC from 0.8127 to 0.743 while AUROC remained at 0.946, indicating that the full fused representation preserves ranking ability but supports a less precise decision boundary

[DOI] [PMC free article] [PubMed] [Google Scholar] 78.Turner JR, Madara JL

doi: 10.1021/acs.jmedchem.7b00389 100 NeelakantanHVanceVWetzelMDWangHLMcHardySFFinnertyCCet al

announced that approximately 14 of the 19 peptides previously placed on the FDAs Category 2 restricted list are expected to be moved back to Category 1restoring legal access through licensed compounding pharmacies under a physicians prescription

Missing doses disrupts the steady-state blood levels that weekly dosing creates